References
Adeyinka, A., Wei, S., & Sanchez, J. (2007). Loss of 17p is a major consequence of whole-arm chromosome translocations in hematologic malignancies. Cancer Genetics and Cytogenetics, 173(2), 136-143. doi:S0165-4608(06)00726-6 [pii]
Alessandrino, E. P., Porta, M. G., Malcovati, L., Jackson, C. H., Pascutto, C., Bacigalupo, A., . . . Gruppo Italiano Trapianto di Midollo Osseo (GITMO). (2013). Optimal timing of allogeneic hematopoietic stem cell transplantation in patients with myelodysplastic syndrome. American Journal of Hematology, 88(7), 581-588. doi:10.1002/ajh.23458 [doi]
Arber, D. A., Orazi, A., Hasserjian, R., Thiele, J., Borowitz, M. J., Le Beau, M. M., . . . Vardiman, J. W.
(2016). The 2016 revision to the world health organization classification of myeloid neoplasms and acute leukemia. Blood, 127(20), 2391-2405. doi:10.1182/blood-2016-03-643544 [doi]
Armand, P., Deeg, H. J., Kim, H. T., Lee, H., Armistead, P., de Lima, M., . . . Soiffer, R. J. (2010).
Multicenter validation study of a transplantation-specific cytogenetics grouping scheme for patients with myelodysplastic syndromes. Bone Marrow Transplantation, 45(5), 877-885.
doi:10.1038/bmt.2009.253 [doi]
Armand, P., Kim, H. T., DeAngelo, D. J., Ho, V. T., Cutler, C. S., Stone, R. M., . . . Soiffer, R. J. (2007).
Impact of cytogenetics on outcome of de novo and therapy-related AML and MDS after allogeneic transplantation. Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation, 13(6), 655-664. doi:S1083-8791(07)00139-5 [pii]
Bacher, U., Haferlach, T., Schnittger, S., Zenger, M., Meggendorfer, M., Jeromin, S., . . . Haferlach, C. (2014). Investigation of 305 patients with myelodysplastic syndromes and 20q deletion for associated cytogenetic and molecular genetic lesions and their prognostic impact. British Journal of Haematology, 164(6), 822-833. doi:10.1111/bjh.12710 [doi]
Badar, T., Patel, K. P., Thompson, P. A., DiNardo, C., Takahashi, K., Cabrero, M., . . .
Garcia-Manero, G. (2015). Detectable FLT3-ITD or RAS mutation at the time of transformation from MDS to AML predicts for very poor outcomes. Leukemia Research, 39(12), 1367-1374.
doi:10.1016/j.leukres.2015.10.005 [doi]
Balleari, E., Rossi, E., Clavio, M., Congiu, A., Gobbi, M., Grosso, M., . . . Ghio, R. (2006).
Erythropoietin plus granulocyte colony-stimulating factor is better than erythropoietin alone to treat anemia in low-risk myelodysplastic syndromes: Results from a randomized single-centre study. Annals of Hematology, 85(3), 174-180. doi:10.1007/s00277-005-0044-6 [doi]
Bally, C., Ades, L., Renneville, A., Sebert, M., Eclache, V., Preudhomme, C., . . . Fenaux, P. (2014).
Prognostic value of TP53 gene mutations in myelodysplastic syndromes and acute myeloid leukemia treated with azacitidine. Leukemia Research, 38(7), 751-755.
doi:10.1016/j.leukres.2014.03.012 [doi]
Bannon, S. A., & DiNardo, C. D. (2016). Hereditary predispositions to myelodysplastic syndrome.
International Journal of Molecular Sciences, 17(6), 10.3390/ijms17060838.
doi:10.3390/ijms17060838 [doi]
Barjesteh van Waalwijk van Doorn-Khosrovani,S., Spensberger, D., de Knegt, Y., Tang, M., Lowenberg, B., & Delwel, R. (2005). Somatic heterozygous mutations in ETV6 (TEL) and frequent absence of ETV6 protein in acute myeloid leukemia. Oncogene, 24(25), 4129-4137. doi:1208588 [pii]
Bejar, R., Levine, R., & Ebert, B. L. (2011). Unraveling the molecular pathophysiology of
myelodysplastic syndromes. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, 29(5), 504-515. doi:10.1200/JCO.2010.31.1175 [doi]
Bejar, R., Stevenson, K., Abdel-Wahab, O., Galili, N., Nilsson, B., Garcia-Manero, G., . . . Ebert, B. L.
(2011). Clinical effect of point mutations in myelodysplastic syndromes. The New England Journal of Medicine, 364(26), 2496-2506. doi:10.1056/NEJMoa1013343 [doi]
Bejar, R., Stevenson, K. E., Caughey, B., Lindsley, R. C., Mar, B. G., Stojanov, P., . . . Ebert, B. L.
(2014). Somatic mutations predict poor outcome in patients with myelodysplastic syndrome after hematopoietic stem-cell transplantation. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, 32(25), 2691-2698. doi:10.1200/JCO.2013.52.3381 [doi]
Bennett, J. M., Catovsky, D., Daniel, M. T., Flandrin, G., Galton, D. A., Gralnick, H. R., & Sultan, C.
(1982). Proposals for the classification of the myelodysplastic syndromes. British Journal of Haematology, 51(2), 189-199.
Bhatia, S. (2013). Therapy-related myelodysplasia and acute myeloid leukemia. Seminars in Oncology, 40(6), 666-675. doi:10.1053/j.seminoncol.2013.09.013 [doi]
Bonnal, S., Vigevani, L., & Valcarcel, J. (2012). The spliceosome as a target of novel antitumour drugs. Nature Reviews.Drug Discovery, 11(11), 847-859. doi:10.1038/nrd3823 [doi]
Boultwood, J., Fidler, C., Strickson, A. J., Watkins, F., Gama, S., Kearney, L., . . . Wainscoat, J. S.
(2002). Narrowing and genomic annotation of the commonly deleted region of the 5q- syndrome.
Blood, 99(12), 4638-4641.
Bowen, D., Culligan, D., Jowitt, S., Kelsey, S., Mufti, G., Oscier, D., . . . UK MDS Guidelines Group.
(2003). Guidelines for the diagnosis and therapy of adult myelodysplastic syndromes. British Journal of Haematology, 120(2), 187-200. doi:3907 [pii]
Bowen, D. T., Fenaux, P., Hellstrom-Lindberg, E., & de Witte, T. (2008). Time-dependent prognostic scoring system for myelodysplastic syndromes has significant limitations that may influence its reproducibility and practical application. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, 26(7), 1180; author reply 1181-2.
doi:10.1200/JCO.2007.15.2926 [doi]
Bueso-Ramos, C. E., Yang, Y., deLeon, E., McCown, P., Stass, S. A., & Albitar, M. (1993). The human MDM-2 oncogene is overexpressed in leukemias. Blood, 82(9), 2617-2623.
Bykov, V. J., Zhang, Q., Zhang, M., Ceder, S., Abrahmsen, L., & Wiman, K. G. (2016). Targeting of mutant p53 and the cellular redox balance by APR-246 as a strategy for efficient cancer therapy.
Frontiers in Oncology, 6, 21. doi:10.3389/fonc.2016.00021 [doi]
Cabrero, M., Wei, Y., Yang, H., Ganan-Gomez, I., Bohannan, Z., Colla, S., . . . Garcia-Manero, G.
(2016). Down-regulation of EZH2 expression in myelodysplastic syndromes. Leukemia Research, 44, 1-7. doi:10.1016/j.leukres.2016.02.009 [doi]
Cao, Q., Gearhart, M. D., Gery, S., Shojaee, S., Yang, H., Sun, H., . . . Koeffler, H. P. (2016). BCOR regulates myeloid cell proliferation and differentiation. Leukemia, 30(5), 1155-1165.
doi:10.1038/leu.2016.2 [doi]
Cerami, E., Gao, J., Dogrusoz, U., Gross, B. E., Sumer, S. O., Aksoy, B. A., . . . Schultz, N. (2012). The cBio cancer genomics portal: An open platform for exploring multidimensional cancer genomics data. Cancer Discovery, 2(5), 401-404. doi:10.1158/2159-8290.CD-12-0095 [doi]
Chaturvedi, A., Araujo Cruz, M. M., Jyotsana, N., Sharma, A., Yun, H., Gorlich, K., . . . Heuser, M.
(2013). Mutant IDH1 promotes leukemogenesis in vivo and can be specifically targeted in human AML. Blood, 122(16), 2877-2887. doi:10.1182/blood-2013-03-491571 [doi]
Chen, C., Liu, Y., Rappaport, A. R., Kitzing, T., Schultz, N., Zhao, Z., . . . Lowe, S. W. (2014). MLL3 is a haploinsufficient 7q tumor suppressor in acute myeloid leukemia. Cancer Cell, 25(5), 652-665.
doi:10.1016/j.ccr.2014.03.016 [doi]
Christiansen, D. H., Andersen, M. K., & Pedersen-Bjergaard, J. (2001). Mutations with loss of heterozygosity of p53 are common in therapy-related myelodysplasia and acute myeloid leukemia after exposure to alkylating agents and significantly associated with deletion or loss of 5q, a complex karyotype, and a poor prognosis. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, 19(5), 1405-1413. doi:10.1200/JCO.2001.19.5.1405 [doi]
Christiansen, D. H., Andersen, M. K., & Pedersen-Bjergaard, J. (2004). Mutations of AML1 are common in therapy-related myelodysplasia following therapy with alkylating agents and are significantly associated with deletion or loss of chromosome arm 7q and with subsequent leukemic transformation. Blood, 104(5), 1474-1481. doi:10.1182/blood-2004-02-0754 [doi]
Christopeit, M., Badbaran, A., Alawi, M., Zabelina, T., Zeck, G., Wolschke, C., . . . Kroger, N. (2016).
Correlation of somatic mutations with outcome after FLAMSA-busulfan sequential conditioning and allogeneic stem cell transplantation in patients with myelodysplastic syndromes. European Journal of Haematology, 97(3), 288-296. doi:10.1111/ejh.12724 [doi]
Chung, C. Y., Lin, S. F., Chen, P. M., Chang, M. C., Kao, W. Y., Chao, T. Y., . . . Chang, C. S. (2012).
Thalidomide for the treatment of myelodysplastic syndrome in taiwan: Results of a phase II trial.
Anticancer Research, 32(8), 3415-3419. doi:32/8/3415 [pii]
Conte, S., Katayama, S., Vesterlund, L., Karimi, M., Dimitriou, M., Jansson, M., . . . Hellstrom-Lindberg, E. (2015). Aberrant splicing of genes involved in haemoglobin synthesis and impaired terminal erythroid maturation in SF3B1 mutated refractory anaemia with ring sideroblasts. British Journal of Haematology, 171(4), 478-490. doi:10.1111/bjh.13610 [doi]
Cordoba, I., Gonzalez-Porras, J. R., Nomdedeu, B., Luno, E., de Paz, R., Such, E., . . . Spanish Myelodysplastic Syndrome Registry. (2012). Better prognosis for patients with del(7q) than for patients with monosomy 7 in myelodysplastic syndrome. Cancer, 118(1), 127-133.
doi:10.1002/cncr.26279 [doi]
Cutler, C. S., Lee, S. J., Greenberg, P., Deeg, H. J., Perez, W. S., Anasetti, C., . . . Horowitz, M. M.
(2004). A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: Delayed transplantation for low-risk myelodysplasia is associated with improved outcome. Blood, 104(2), 579-585. doi:10.1182/blood-2004-01-0338 [doi]
Damm, F., Chesnais, V., Nagata, Y., Yoshida, K., Scourzic, L., Okuno, Y., . . . Kosmider, O. (2013).
BCOR and BCORL1 mutations in myelodysplastic syndromes and related disorders. Blood, 122(18), 3169-3177. doi:10.1182/blood-2012-11-469619 [doi]
Damm, F., Thol, F., Kosmider, O., Kade, S., Loffeld, P., Dreyfus, F., . . . Heuser, M. (2012). SF3B1 mutations in myelodysplastic syndromes: Clinical associations and prognostic implications.
Leukemia, 26(5), 1137-1140. doi:10.1038/leu.2011.321 [doi]
Dang, L., White, D. W., Gross, S., Bennett, B. D., Bittinger, M. A., Driggers, E. M., . . . Su, S. M.
(2010). Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature, 465(7300), 966.
doi:10.1038/nature09132 [doi]
Darman, R. B., Seiler, M., Agrawal, A. A., Lim, K. H., Peng, S., Aird, D., . . . Buonamici, S. (2015).
Cancer-associated SF3B1 hotspot mutations induce cryptic 3' splice site selection through use of a different branch point. Cell Reports, 13(5), 1033-1045. doi:10.1016/j.celrep.2015.09.053 [doi]
Davidsson, J., Puschmann, A., Tedgard, U., Bryder, D., Nilsson, L., & Cammenga, J. (2018). SAMD9 and SAMD9L in inherited predisposition to ataxia, pancytopenia, and myeloid malignancies.
Leukemia, doi:10.1038/s41375-018-0074-4 [doi]
de Witte, T., Bowen, D., Robin, M., Malcovati, L., Niederwieser, D., Yakoub-Agha, I., . . . Kroger, N.
(2017). Allogeneic hematopoietic stem cell transplantation for MDS and CMML:
Recommendations from an international expert panel. Blood, 129(13), 1753-1762.
doi:10.1182/blood-2016-06-724500 [doi]
de Witte, T., Hagemeijer, A., Suciu, S., Belhabri, A., Delforge, M., Kobbe, G., . . . Willemze, R.
(2010). Value of allogeneic versus autologous stem cell transplantation and chemotherapy in patients with myelodysplastic syndromes and secondary acute myeloid leukemia. final results of a prospective randomized european intergroup trial. Haematologica, 95(10), 1754-1761.
doi:10.3324/haematol.2009.019182 [doi]
Deeg, H. J., Scott, B. L., Fang, M., Shulman, H. M., Gyurkocza, B., Myerson, D., . . . Gooley, T.
(2012). Five-group cytogenetic risk classification, monosomal karyotype, and outcome after hematopoietic cell transplantation for MDS or acute leukemia evolving from MDS. Blood, 120(7), 1398-1408. doi:10.1182/blood-2012-04-423046 [doi]
Della Porta, M. G., Alessandrino, E. P., Bacigalupo, A., van Lint, M. T., Malcovati, L., Pascutto, C., . . . Gruppo Italiano Trapianto di Midollo Osseo. (2014). Predictive factors for the outcome of allogeneic transplantation in patients with MDS stratified according to the revised IPSS-R. Blood, 123(15), 2333-2342. doi:10.1182/blood-2013-12-542720 [doi]
Della Porta, M. G., Galli, A., Bacigalupo, A., Zibellini, S., Bernardi, M., Rizzo, E., . . . Cazzola, M.
(2016). Clinical effects of driver somatic mutations on the outcomes of patients with
myelodysplastic syndromes treated with allogeneic hematopoietic stem-cell transplantation.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, doi:JCO673616 [pii]
Della Porta, M. G., Tuechler, H., Malcovati, L., Schanz, J., Sanz, G., Garcia-Manero, G., . . . Cazzola, M. (2015). Validation of WHO classification-based prognostic scoring system (WPSS) for
myelodysplastic syndromes and comparison with the revised international prognostic scoring system (IPSS-R). A study of the international working group for prognosis in myelodysplasia (IWG-PM). Leukemia, 29(7), 1502-1513. doi:10.1038/leu.2015.55 [doi]
Dicker, F., Haferlach, C., Sundermann, J., Wendland, N., Weiss, T., Kern, W., . . . Schnittger, S.
(2010a). Mutation analysis for RUNX1, MLL-PTD, FLT3-ITD, NPM1 and NRAS in 269 patients with MDS or secondary AML. Leukemia, 24(8), 1528-1532. doi:10.1038/leu.2010.124 [doi]
Dicker, F., Haferlach, C., Sundermann, J., Wendland, N., Weiss, T., Kern, W., . . . Schnittger, S.
(2010b). Mutation analysis for RUNX1, MLL-PTD, FLT3-ITD, NPM1 and NRAS in 269 patients with MDS or secondary AML. Leukemia, 24(8), 1528-1532. doi:10.1038/leu.2010.124 [doi]
Ding, Q., Zhang, Z., Liu, J. J., Jiang, N., Zhang, J., Ross, T. M., . . . Graves, B. (2013). Discovery of RG7388, a potent and selective p53-MDM2 inhibitor in clinical development. Journal of Medicinal Chemistry, 56(14), 5979-5983. doi:10.1021/jm400487c [doi]
Dohner, K., Brown, J., Hehmann, U., Hetzel, C., Stewart, J., Lowther, G., . . . Dohner, H. (1998).
Molecular cytogenetic characterization of a critical region in bands 7q35-q36 commonly deleted in malignant myeloid disorders. Blood, 92(11), 4031-4035.
Dokal, I. (2000). Dyskeratosis congenita in all its forms. British Journal of Haematology, 110(4), 768-779. doi:bjh2109 [pii]
Donadieu, J., Leblanc, T., Bader Meunier, B., Barkaoui, M., Fenneteau, O., Bertrand, Y., . . . French Severe Chronic Neutropenia Study Group. (2005). Analysis of risk factors for myelodysplasias, leukemias and death from infection among patients with congenital neutropenia. experience of the french severe chronic neutropenia study group. Haematologica, 90(1), 45-53.
Ebert, B. L., Pretz, J., Bosco, J., Chang, C. Y., Tamayo, P., Galili, N., . . . Golub, T. R. (2008).
Identification of RPS14 as a 5q- syndrome gene by RNA interference screen. Nature, 451(7176), 335-339. doi:10.1038/nature06494 [doi]
Fenaux, P., Giagounidis, A., Selleslag, D., Beyne-Rauzy, O., Mufti, G., Mittelman, M., . . . MDS-004 Lenalidomide del5q Study Group. (2011). A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with low-/intermediate-1-risk myelodysplastic syndromes with del5q. Blood, 118(14), 3765-3776. doi:10.1182/blood-2011-01-330126 [doi]
Fenaux, P., Mufti, G. J., Hellstrom-Lindberg, E., Santini, V., Finelli, C., Giagounidis, A., . . .
International Vidaza High-Risk MDS Survival Study Group. (2009). Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic
syndromes: A randomised, open-label, phase III study. The Lancet.Oncology, 10(3), 223-232.
doi:10.1016/S1470-2045(09)70003-8 [doi]
Fenrick, R., Wang, L., Nip, J., Amann, J. M., Rooney, R. J., Walker-Daniels, J., . . . Hiebert, S. W.
(2000). TEL, a putative tumor suppressor, modulates cell growth and cell morphology of ras-transformed cells while repressing the transcription of stromelysin-1. Molecular and Cellular Biology, 20(16), 5828-5839.
Figueroa, M. E., Abdel-Wahab, O., Lu, C., Ward, P. S., Patel, J., Shih, A., . . . Melnick, A. (2010).
Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell, 18(6), 553-567.
doi:10.1016/j.ccr.2010.11.015 [doi]
Fisher, C. L., Pineault, N., Brookes, C., Helgason, C. D., Ohta, H., Bodner, C., . . . Brock, H. W.
(2010). Loss-of-function additional sex combs like 1 mutations disrupt hematopoiesis but do not cause severe myelodysplasia or leukemia. Blood, 115(1), 38-46. doi:10.1182/blood-2009-07-230698 [doi]
Fisher, C. L., Randazzo, F., Humphries, R. K., & Brock, H. W. (2006). Characterization of Asxl1, a murine homolog of additional sex combs, and analysis of the asx-like gene family. Gene, 369, 109-118. doi:S0378-1119(05)00659-1 [pii]
Gallagher, A., Darley, R., & Padua, R. A. (1997). RAS and the myelodysplastic syndromes.
Pathologie-Biologie, 45(7), 561-568.
Gao, J., Aksoy, B. A., Dogrusoz, U., Dresdner, G., Gross, B., Sumer, S. O., . . . Schultz, N. (2013).
Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Science Signaling, 6(269), pl1. doi:10.1126/scisignal.2004088 [doi]
Gerstung, M., Papaemmanuil, E., Martincorena, I., Bullinger, L., Gaidzik, V. I., Paschka, P., . . . Campbell, P. J. (2017). Precision oncology for acute myeloid leukemia using a knowledge bank approach. Nature Genetics, 49(3), 332-340. doi:10.1038/ng.3756 [doi]
Golub, T. R., Goga, A., Barker, G. F., Afar, D. E., McLaughlin, J., Bohlander, S. K., . . . Gilliland, D. G.
(1996). Oligomerization of the ABL tyrosine kinase by the ets protein TEL in human leukemia.
Molecular and Cellular Biology, 16(8), 4107-4116.
Gottlicher, M., Minucci, S., Zhu, P., Kramer, O. H., Schimpf, A., Giavara, S., . . . Heinzel, T. (2001).
Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells.
The EMBO Journal, 20(24), 6969-6978. doi:10.1093/emboj/20.24.6969 [doi]
Gratwohl, A., Baldomero, H., Schwendener, A., Rocha, V., Apperley, J., Frauendorfer, K., . . . European Group for Blood and Marrow Transplantation. (2009). The EBMT activity survey 2007 with focus on allogeneic HSCT for AML and novel cellular therapies. Bone Marrow
Transplantation, 43(4), 275-291. doi:10.1038/bmt.2009.7 [doi]
Graubert, T. A., Payton, M. A., Shao, J., Walgren, R. A., Monahan, R. S., Frater, J. L., . . . Walter, M.
J. (2009). Integrated genomic analysis implicates haploinsufficiency of multiple chromosome 5q31.2 genes in de novo myelodysplastic syndromes pathogenesis. PloS One, 4(2), e4583.
doi:10.1371/journal.pone.0004583 [doi]
Graubert, T. A., Shen, D., Ding, L., Okeyo-Owuor, T., Lunn, C. L., Shao, J., . . . Walter, M. J. (2011).
Recurrent mutations in the U2AF1 splicing factor in myelodysplastic syndromes. Nature Genetics, 44(1), 53-57. doi:10.1038/ng.1031 [doi]
Gray, R. J. (1988). A class of K-sample tests for comparing the cumulative incidence of a competing risk. The Annals of Statistics, 16(3), 1141-1154.
Greenberg, P., Cox, C., LeBeau, M. M., Fenaux, P., Morel, P., Sanz, G., . . . Bennett, J. (1997).
International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood, 89(6), 2079-2088.
Greenberg, P. L., Tuechler, H., Schanz, J., Sanz, G., Garcia-Manero, G., Sole, F., . . . Haase, D.
(2012). Revised international prognostic scoring system for myelodysplastic syndromes. Blood, 120(12), 2454-2465. doi:blood-2012-03-420489 [pii]
Grossmann, V., Tiacci, E., Holmes, A. B., Kohlmann, A., Martelli, M. P., Kern, W., . . . Falini, B.
(2011). Whole-exome sequencing identifies somatic mutations of BCOR in acute myeloid leukemia with normal karyotype. Blood, 118(23), 6153-6163. doi:10.1182/blood-2011-07-365320 [doi]
Haase, D., Germing, U., Schanz, J., Pfeilstocker, M., Nosslinger, T., Hildebrandt, B., . . . Steidl, C.
(2007). New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: Evidence from a core dataset of 2124 patients. Blood, 110(13), 4385-4395. doi:blood-2007-03-082404 [pii]
Haferlach, T., Nagata, Y., Grossmann, V., Okuno, Y., Bacher, U., Nagae, G., . . . Ogawa, S. (2014).
Landscape of genetic lesions in 944 patients with myelodysplastic syndromes. Leukemia, 28(2), 241-247. doi:10.1038/leu.2013.336 [doi]
Hahn, C. N., Chong, C. E., Carmichael, C. L., Wilkins, E. J., Brautigan, P. J., Li, X. C., . . . Scott, H. S.
(2011). Heritable GATA2 mutations associated with familial myelodysplastic syndrome and acute myeloid leukemia. Nature Genetics, 43(10), 1012-1017. doi:10.1038/ng.913 [doi]
Harutyunyan, A., Klampfl, T., Cazzola, M., & Kralovics, R. (2011). P53 lesions in leukemic transformation. The New England Journal of Medicine, 364(5), 488-490.
doi:10.1056/NEJMc1012718 [doi]
Heinrichs, S., Kulkarni, R. V., Bueso-Ramos, C. E., Levine, R. L., Loh, M. L., Li, C., . . . Look, A. T.
(2009). Accurate detection of uniparental disomy and microdeletions by SNP array analysis in myelodysplastic syndromes with normal cytogenetics. Leukemia, 23(9), 1605-1613.
doi:10.1038/leu.2009.82 [doi]
Hellstrom-Lindberg, E., Robert, K. H., Gahrton, G., Lindberg, G., Forsblom, A. M., Kock, Y., & Ost, A.
(1992). A predictive model for the clinical response to low dose ara-C: A study of 102 patients with myelodysplastic syndromes or acute leukaemia. British Journal of Haematology, 81(4), 503-511.
Herzog, G., Lu-Hesselmann, J., Zimmermann, Y., Haferlach, T., Hiddemann, W., & Dreyling, M.
(2005). Microsatellite instability and p53 mutations are characteristic of subgroups of acute myeloid leukemia but independent events. Haematologica, 90(5), 693-695.
Heuser, M. (2016). Therapy-related myeloid neoplasms: Does knowing the origin help to guide treatment? Hematology.American Society of Hematology.Education Program, 2016(1), 24-32.
doi:2016/1/24 [pii]
Heuser, M., Gabdoulline, R., Loffeld, P., Dobbernack, V., Kreimeyer, H., Pankratz, M., . . . Thol, F.
(2017). Individual outcome prediction for myelodysplastic syndrome (MDS) and secondary acute myeloid leukemia from MDS after allogeneic hematopoietic cell transplantation. Annals of Hematology, 96(8), 1361-1372. doi:10.1007/s00277-017-3027-5 [doi]
Heuser, M., Meggendorfer, M., Cruz, M. M., Fabisch, J., Klesse, S., Kohler, L., . . . Thol, F. (2015).
Frequency and prognostic impact of casein kinase 1A1 mutations in MDS patients with deletion of chromosome 5q. Leukemia, 29(9), 1942-1945. doi:10.1038/leu.2015.49 [doi]
Heuser, M., Yap, D. B., Leung, M., de Algara, T. R., Tafech, A., McKinney, S., . . . Aparicio, S. A.
(2009). Loss of MLL5 results in pleiotropic hematopoietic defects, reduced neutrophil immune function, and extreme sensitivity to DNA demethylation. Blood, 113(7), 1432-1443.
doi:10.1182/blood-2008-06-162263 [doi]
Higgins, B., Tovar, C., Glenn, K., Walz, A., Fillipovic, Z., Zhang, Y., . . . Packman, K. (2013). Abstract B55: Antitumor activity of the MDM2 antagonist RG7388. Molecular Targets and Cancer
Therapeutics,
Horiike, S., Kita-Sasai, Y., Nakao, M., & Taniwaki, M. (2003). Configuration of the TP53 gene as an independent prognostic parameter of myelodysplastic syndrome. Leukemia & Lymphoma, 44(6), 915-922. doi:10.1080/1042819031000067620 [doi]
Horrigan, S. K., Arbieva, Z. H., Xie, H. Y., Kravarusic, J., Fulton, N. C., Naik, H., . . . Westbrook, C. A.
(2000). Delineation of a minimal interval and identification of 9 candidates for a tumor suppressor gene in malignant myeloid disorders on 5q31. Blood, 95(7), 2372-2377.
Hou, Y., Song, L., Zhu, P., Zhang, B., Tao, Y., Xu, X., . . . Wang, J. (2012). Single-cell exome sequencing and monoclonal evolution of a JAK2-negative myeloproliferative neoplasm. Cell, 148(5), 873-885. doi:10.1016/j.cell.2012.02.028 [doi]
Huynh, K. D., Fischle, W., Verdin, E., & Bardwell, V. J. (2000). BCoR, a novel corepressor involved in BCL-6 repression. Genes & Development, 14(14), 1810-1823.
Ichikawa, M., Yoshimi, A., Nakagawa, M., Nishimoto, N., Watanabe-Okochi, N., & Kurokawa, M.
(2013). A role for RUNX1 in hematopoiesis and myeloid leukemia. International Journal of Hematology, 97(6), 726-734. doi:10.1007/s12185-013-1347-3 [doi]
Inoue, D., Matsumoto, M., Nagase, R., Saika, M., Fujino, T., Nakayama, K. I., & Kitamura, T. (2016).
Truncation mutants of ASXL1 observed in myeloid malignancies are expressed at detectable protein levels. Experimental Hematology, 44(3), 172-6.e1. doi:10.1016/j.exphem.2015.11.011 [doi]
Italian Cooperative Study Group for rHuEpo in Myelodysplastic Syndromes, Ferrini, P. R., Grossi, A., Vannucchi, A. M., Barosi, G., Guarnone, R., . . . Balleari, E. (1998). A randomized double-blind placebo-controlled study with subcutaneous recombinant human erythropoietin in patients with low-risk myelodysplastic syndromes. British Journal of Haematology, 103(4), 1070-1074.
Ito, Y. (2004). Oncogenic potential of the RUNX gene family: 'Overview'. Oncogene, 23(24), 4198-4208. doi:10.1038/sj.onc.1207755 [doi]
Itzykson, R., Kosmider, O., Cluzeau, T., Mansat-De Mas, V., Dreyfus, F., Beyne-Rauzy, O., . . . Groupe Francophone des Myelodysplasies (GFM). (2011). Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias.
Leukemia, 25(7), 1147-1152. doi:10.1038/leu.2011.71 [doi]
Jadersten, M., Saft, L., Pellagatti, A., Gohring, G., Wainscoat, J. S., Boultwood, J., . . . Hellstrom-Lindberg, E. (2009). Clonal heterogeneity in the 5q- syndrome: p53 expressing progenitors prevail during lenalidomide treatment and expand at disease progression. Haematologica, 94(12), 1762-1766. doi:10.3324/haematol.2009.011528 [doi]
Jankowska, A. M., Szpurka, H., Tiu, R. V., Makishima, H., Afable, M., Huh, J., . . . Maciejewski, J. P.
(2009). Loss of heterozygosity 4q24 and TET2 mutations associated with
myelodysplastic/myeloproliferative neoplasms. Blood, 113(25), 6403-6410. doi:10.1182/blood-2009-02-205690 [doi]
Janov, A. J., Leong, T., Nathan, D. G., & Guinan, E. C. (1996). Diamond-blackfan anemia. natural history and sequelae of treatment. Medicine, 75(2), 77-78.
Joslin, J. M., Fernald, A. A., Tennant, T. R., Davis, E. M., Kogan, S. C., Anastasi, J., . . . Le Beau, M. M.
(2007). Haploinsufficiency of EGR1, a candidate gene in the del(5q), leads to the development of myeloid disorders. Blood, 110(2), 719-726. doi:blood-2007-01-068809 [pii]
Kantarjian, H., Beran, M., Cortes, J., O'Brien, S., Giles, F., Pierce, S., . . . Estey, E. (2006). Long-term follow-up results of the combination of topotecan and cytarabine and other intensive
chemotherapy regimens in myelodysplastic syndrome. Cancer, 106(5), 1099-1109.
doi:10.1002/cncr.21699 [doi]
Kim, E., Ilagan, J. O., Liang, Y., Daubner, G. M., Lee, S. C., Ramakrishnan, A., . . . Abdel-Wahab, O.
(2015). SRSF2 mutations contribute to myelodysplasia by mutant-specific effects on exon recognition. Cancer Cell, 27(5), 617-630. doi:10.1016/j.ccell.2015.04.006 [doi]
Kirwan, M., Walne, A. J., Plagnol, V., Velangi, M., Ho, A., Hossain, U., . . . Dokal, I. (2012). Exome sequencing identifies autosomal-dominant SRP72 mutations associated with familial aplasia and myelodysplasia. American Journal of Human Genetics, 90(5), 888-892.
doi:10.1016/j.ajhg.2012.03.020 [doi]
Knipp, S., Hildebrand, B., Kundgen, A., Giagounidis, A., Kobbe, G., Haas, R., . . . Germing, U. (2007).
Intensive chemotherapy is not recommended for patients aged >60 years who have
myelodysplastic syndromes or acute myeloid leukemia with high-risk karyotypes. Cancer, 110(2), 345-352. doi:10.1002/cncr.22779 [doi]
Komrokji, R. S. (2016). Current state of the art: Management of higher risk myelodysplastic syndromes. Clinical Lymphoma, Myeloma & Leukemia, 16 Suppl, S39-43.
doi:10.1016/j.clml.2016.02.019 [doi]
Koreth, J., Pidala, J., Perez, W. S., Deeg, H. J., Garcia-Manero, G., Malcovati, L., . . . Cutler, C.
(2013). Role of reduced-intensity conditioning allogeneic hematopoietic stem-cell transplantation in older patients with de novo myelodysplastic syndromes: An international collaborative decision analysis. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, 31(21), 2662-2670. doi:10.1200/JCO.2012.46.8652 [doi]
Kuendgen, A., Strupp, C., Aivado, M., Bernhardt, A., Hildebrandt, B., Haas, R., . . . Gattermann, N.
(2004). Treatment of myelodysplastic syndromes with valproic acid alone or in combination with all-trans retinoic acid. Blood, 104(5), 1266-1269. doi:10.1182/blood-2003-12-4333 [doi]
Lai, J. L., Preudhomme, C., Zandecki, M., Flactif, M., Vanrumbeke, M., Lepelley, P., . . . Fenaux, P.
(1995). Myelodysplastic syndromes and acute myeloid leukemia with 17p deletion. an entity characterized by specific dysgranulopoiesis and a high incidence of P53 mutations. Leukemia, 9(3), 370-381.
Langemeijer, S. M., Kuiper, R. P., Berends, M., Knops, R., Aslanyan, M. G., Massop, M., . . . Jansen, J. H. (2009). Acquired mutations in TET2 are common in myelodysplastic syndromes. Nature Genetics, 41(7), 838-842. doi:10.1038/ng.391 [doi]
Lawrence, M. S., Stojanov, P., Mermel, C. H., Robinson, J. T., Garraway, L. A., Golub, T. R., . . . Getz, G. (2014). Discovery and saturation analysis of cancer genes across 21 tumour types. Nature, 505(7484), 495-501. doi:10.1038/nature12912 [doi]
Le Beau, M. M., Espinosa, R.,3rd, Davis, E. M., Eisenbart, J. D., Larson, R. A., & Green, E. D. (1996).
Cytogenetic and molecular delineation of a region of chromosome 7 commonly deleted in malignant myeloid diseases. Blood, 88(6), 1930-1935.
Le Pogam, C., Krief, P., Beurlet, S., Soulie, A., Balitrand, N., Cassinat, B., . . . Omidvar, N. (2013).
Localization of the NRAS:BCL-2 complex determines anti-apoptotic features associated with progressive disease in myelodysplastic syndromes. Leukemia Research, 37(3), 312-319.
doi:10.1016/j.leukres.2012.10.018 [doi]
Ley, T. J., Ding, L., Walter, M. J., McLellan, M. D., Lamprecht, T., Larson, D. E., . . . Wilson, R. K.
(2010). DNMT3A mutations in acute myeloid leukemia. The New England Journal of Medicine, 363(25), 2424-2433. doi:10.1056/NEJMoa1005143 [doi]
Li, Z., Zhang, P., Yan, A., Guo, Z., Ban, Y., Li, J., . . . Yang, F. C. (2017). ASXL1 interacts with the cohesin complex to maintain chromatid separation and gene expression for normal
hematopoiesis. Science Advances, 3(1), e1601602. doi:10.1126/sciadv.1601602 [doi]
Lindsley, R. C., Saber, W., Mar, B. G., Redd, R., Wang, T., Haagenson, M. D., . . . Ebert, B. L. (2017).
Prognostic mutations in myelodysplastic syndrome after stem-cell transplantation. The New England Journal of Medicine, 376(6), 536-547. doi:10.1056/NEJMoa1611604 [doi]
List, A., Kurtin, S., Roe, D. J., Buresh, A., Mahadevan, D., Fuchs, D., . . . Zeldis, J. B. (2005). Efficacy of lenalidomide in myelodysplastic syndromes. The New England Journal of Medicine, 352(6), 549-557. doi:352/6/549 [pii]
List, A. F., Baer, M. R., Steensma, D. P., Raza, A., Esposito, J., Martinez-Lopez, N., . . . Besa, E.
(2012). Deferasirox reduces serum ferritin and labile plasma iron in RBC transfusion-dependent patients with myelodysplastic syndrome. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, 30(17), 2134-2139. doi:10.1200/JCO.2010.34.1222 [doi]
List, A. F., Bennett, J. M., Sekeres, M. A., Skikne, B., Fu, T., Shammo, J. M., . . . MDS-003 Study Investigators. (2014). Extended survival and reduced risk of AML progression in erythroid-responsive lenalidomide-treated patients with lower-risk del(5q) MDS. Leukemia, 28(5), 1033-1040. doi:10.1038/leu.2013.305 [doi]
Liu, T. X., Becker, M. W., Jelinek, J., Wu, W. S., Deng, M., Mikhalkevich, N., . . . Look, A. T. (2007).
Chromosome 5q deletion and epigenetic suppression of the gene encoding alpha-catenin (CTNNA1) in myeloid cell transformation. Nature Medicine, 13(1), 78-83. doi:nm1512 [pii]
Lopez, R. G., Carron, C., Oury, C., Gardellin, P., Bernard, O., & Ghysdael, J. (1999). TEL is a sequence-specific transcriptional repressor. The Journal of Biological Chemistry, 274(42), 30132-30138.
Losman, J. A., Looper, R. E., Koivunen, P., Lee, S., Schneider, R. K., McMahon, C., . . . Kaelin, W.
G.,Jr. (2013). (R)-2-hydroxyglutarate is sufficient to promote leukemogenesis and its effects are reversible. Science (New York, N.Y.), 339(6127), 1621-1625. doi:10.1126/science.1231677 [doi]
Lubbert, M., Wijermans, P., Kunzmann, R., Verhoef, G., Bosly, A., Ravoet, C., . . . Ferrant, A. (2001).
Cytogenetic responses in high-risk myelodysplastic syndrome following low-dose treatment with the DNA methylation inhibitor 5-aza-2'-deoxycytidine. British Journal of Haematology, 114(2), 349-357. doi:bjh2933 [pii]
Ma, X., Does, M., Raza, A., & Mayne, S. T. (2007). Myelodysplastic syndromes: Incidence and survival in the united states. Cancer, 109(8), 1536-1542. doi:10.1002/cncr.22570 [doi]
Makishima, H., Yoshizato, T., Yoshida, K., Sekeres, M. A., Radivoyevitch, T., Suzuki, H., . . . Maciejewski, J. P. (2017). Dynamics of clonal evolution in myelodysplastic syndromes. Nature Genetics, 49(2), 204-212. doi:10.1038/ng.3742 [doi]
Malcovati, L., Della Porta, M. G., Strupp, C., Ambaglio, I., Kuendgen, A., Nachtkamp, K., . . . Cazzola, M. (2011). Impact of the degree of anemia on the outcome of patients with myelodysplastic syndrome and its integration into the WHO classification-based prognostic
scoring system (WPSS). Haematologica, 96(10), 1433-1440. doi:10.3324/haematol.2011.044602 [doi]
Malcovati, L., Germing, U., Kuendgen, A., Della Porta, M. G., Pascutto, C., Invernizzi, R., . . . Cazzola, M. (2007). Time-dependent prognostic scoring system for predicting survival and
Malcovati, L., Germing, U., Kuendgen, A., Della Porta, M. G., Pascutto, C., Invernizzi, R., . . . Cazzola, M. (2007). Time-dependent prognostic scoring system for predicting survival and